Latest News by Industry
BRISBANE, Calif.--(BUSINESS WIRE)--Feb 28, 2023--
Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the fourth quarter and full-year ended December 31, 2022.
Fourth Quarter 2022 Financial and Operational Highlights
Full-Year 2022 Financial and Operational Highlights
| Key Revenue Metrics | Three Months Ended Dec 31, 2022 | % Change 2022 Vs 2021 | Constant Currency | Key Profit Metrics | Three Months Ended Dec 31, 2022 | Constant Currency | ||||||||
| Capital Equipment | $ | 42.5 | -2 | % | 1 | % | GAAP Margin % |
| 57.5 | % |
| 59.8 | % | |
| Skincare | $ | 11.8 | 10 | % | 37 | % | Non-GAAP Margin % |
| 59.4 | % |
| 61.5 | % | |
| Consumables | $ | 4.2 | -22 | % | -18 | % | Adjusted EBITDA - Core | $ | 4.7 |
| $ | 8.2 |
| |
| Service | $ | 5.8 | -4 | % | 2 | % | Adjusted EBITDA - AviClear | ($ | 4.4 | ) | ($ | 4.5 | ) | |
| AviClear | $ | 3.2 | N/A | N/A | Adjusted EBITDA - Total | $ | 0.2 |
| $ | 3.7 |
| |||
| Recurring | $ | 24.9 | 13 | % | 29 | % | Adjusted EBITDA Gross Margin % |
| 0.4 | % |
| 5.1 | % | |
| Total Revenue | $ | 67.4 | 3 | % | 10 | % | ||||||||
| Key Revenue Metrics | Twelve Months Ended Dec 31, 2022 | % Change 2022 Vs 2021 | Constant Currency | Key Profit Metrics | Twelve Months Ended Dec 31, 2022 | Constant Currency | ||||||||
| Capital Equipment | $ | 163.6 | 17 | % | 21 | % | GAAP Margin % |
| 55.4 | % |
| 57.4 | % | |
| Skincare | $ | 42.5 | -14 | % | 1 | % | Non-GAAP Margin % |
| 56.6 | % |
| 58.5 | % | |
| Consumables | $ | 18.2 | 11 | % | 16 | % | Adjusted EBITDA - Core | $ | 20.9 |
| $ | 31.5 |
| |
| Service | $ | 23.6 | -8 | % | -3 | % | Adjusted EBITDA - AviClear | ($ | 28.0 | ) | ($ | 28.1 | ) | |
| AviClear | $ | 4.5 | N/A | N/A | Adjusted EBITDA - Total | ($ | 7.2 | ) | $ | 3.4 |
| |||
| Recurring | $ | 88.8 | -3 | % | 8 | % | Adjusted EBITDA Gross Margin % |
| -2.8 | % |
| 1.3 | % | |
| Total Revenue | $ | 252.4 | 9 | % | 16 | % |
“2022 was a year to be remembered for Cutera, as the sales teams delivered mid-teens full-year growth on a constant currency basis in the face of global macro-economic pressures. Meanwhile, we successfully launched and scaled operations for AviClear, our first-to-market revolutionary laser device for the treatment of acne. In just three quarters since our North American introduction we have begun to see green shoots of the financial profile transformation we envision with the application of our novel AviClear business model,” commented Dave Mowry, Chief Executive Officer of Cutera, Inc.
Mowry continued, “Looking back over fourth quarter 2022 AviClear results, I was especially pleased to see the broad acceptance and significant ramp of AviClear bookings in the period. Our focus on leading with clinical results; supporting practice expansion; and delivering improved patient outcomes with reduced patient risk profile is resonating with the dermatologists as market demand outpaced expectations and our ability to fulfill it, at least in the short-term. We intend to continue our efforts to place the customer at the center of our partnership approach, as illustrated by the recent introduction of the AviClear Rewards customer loyalty program which tightly aligns our interests with those of our customers. This program will unlock even greater practice profitability with increased treatments. Additionally, practices owners will be able to leverage their AviClear patient volumes to access cooperative marketing dollars to promote their practice as well as our AviClear procedure.”
2023 Outlook
The company expects full-year 2023 revenue in the range of $277 million to $292 million, implying 10% to 16% constant currency growth over the prior year. The company also expects adjusted EBITDA to be in the low single-digit millions of dollars with consistent, sequential improvement as we progress through the year. Finally, the company anticipates steady placements of the AviClear device each quarter at a rate between 200 – 300 units per quarter over the course of 2023.
Conference Call
The Company’s management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating in the call will be Dave Mowry, Chief Executive Officer, and Rohan Seth, Chief Financial Officer.
To participate in the conference call, dial 1-800-319-4610 (domestic) or + 1-631-891-4304 (international).
The call will also be a webcast and can be accessed from the Investor Relations section of Cutera’s website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com.
*Use of Non-GAAP Financial Measures
In this press release, to supplement the Company ’ s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for gross margin, gross margin rate, and operating income. Non-GAAP adjustments include stock-based compensation, depreciation and amortization including contract acquisition costs, executive and other non-recurring severance costs, enterprise resource planning ( “ ERP ” ) implementation costs, and certain legal and litigation costs. From time to time in the future, there may be other items that we may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.
The Company defines adjusted EBITDA as operating income before depreciation and amortization, stock-based compensation, executive and non-recurring severance costs, ERP implementataion costs, and costs related to a specific litigation.
Company management uses non-GAAP measurements as aids in monitoring the Company ’ s ongoing financial performance from quarter to quarter, and year to year, regularly and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:
Stock-based compensation.The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;
Depreciation and amortization, including contract acquisition costs.The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;
Executive and other non-recurring severance costs.We have excluded costs associated with restructuring activities and the separation of our officers and other executives in calculating our non-GAAP operating expenses and non-GAAP Operating Income. We have excluded restructuring costs because a restructuring represents a discrete event that signifies a change in our strategy, but its costs are not indicative of the ongoing financial performance of our business. We exclude executive separation costs because executive separations are unpredictable and not part of our business strategy but could have a significant impact on the results of operation;;
ERP implementation costs.We have excluded ERP system costs related to direct and incremental costs incurred in connection with our multi-phase implementation of a new ERP solution and the related technology infrastructure costs. We exclude these costs because we believe that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance; and
Certain legal and litigation costs.We have excluded costs incurred related to our litigation against Lutronic Aesthetics, which is not part of our ordinary course of business. Our complaint against Lutronic alleges misappropriation of trade secrets, violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), interference with contractual relations and other claims. We exclude these costs because this litigation is a result of a discrete event that was not part of our business strategy but has a significant effect on the results of operations. Its costs are incidental to and do not reflect the efficiencies and effectiveness of our core operations.
The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations.
Safe Harbor Statement
Certain statements in this press release, other than purely historical information, are “ forward-looking statements ” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ” ). These statements include but are not limited to, Cutera ’ s plans, objectives, strategies, financial performance and outlook, product launches and performance, trends, prospects, or future events and involve known and unknown risks that are difficult to predict. As a result, the Company ’ s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “ may, ” “ could, ” “ seek, ” “ guidance, ” “ predict, ” “ potential, ” “ likely, ” “ believe, ” “ will, ” “ should, ” “ expect, ” “ anticipate, ” “ estimate, ” “ plan, ” “ intend, ” “ forecast, ” “ foresee ” or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond the Company ’ s control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “ Risk Factors ” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-8 and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.
All information in this press release is as of the date of its release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera's financial performance for the fourth quarter and full-year ended December 31, 2022, as discussed in this release, is preliminary and unaudited, and subject to adjustment.
CUTERA, INC. | |||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(in thousands) | |||||||
(unaudited) | |||||||
December 31, |
| December 31, | |||||
2022 |
| 2021 | |||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 145,924 |
| $ | 164,164 |
| |
| Marketable investments |
| 171,390 |
|
| - |
| |
| Accounts receivable, net |
| 45,562 |
|
| 31,449 |
| |
| Inventories, net |
| 63,628 |
|
| 39,503 |
| |
| Other current assets and prepaid expenses |
| 24,036 |
|
| 14,545 |
| |
| Restricted cash |
| 700 |
|
| - |
| |
| Total current assets |
| 451,240 |
|
| 249,661 |
| |
| Property and equipment, net |
| 40,368 |
|
| 3,019 |
| |
| Deferred tax assets |
| 590 |
|
| 778 |
| |
| Goodwill |
| 1,339 |
|
| 1,339 |
| |
| Operating lease right-of-use assets |
| 12,831 |
|
| 14,627 |
| |
| Other long-term assets |
| 14,620 |
|
| 10,169 |
| |
| Restricted cash |
| - |
|
| 700 |
| |
| Total assets | $ | 520,988 |
| $ | 280,293 |
| |
| Liabilities and Stockholders' Equity (Deficit) | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 33,736 |
| $ | 7,891 |
| |
| Accrued liabilities |
| 57,452 |
|
| 54,100 |
| |
| Operating leases liabilities |
| 2,810 |
|
| 2,419 |
| |
| Deferred revenue |
| 11,841 |
|
| 9,490 |
| |
| Total current liabilities |
| 105,839 |
|
| 73,900 |
| |
| Deferred revenue, net of current portion |
| 1,657 |
|
| 1,335 |
| |
| Operating lease liabilities, net of current portion |
| 11,352 |
|
| 13,483 |
| |
| Convertible notes, net of unamortized debt issuance costs |
| 416,459 |
|
| 134,243 |
| |
| Other long-term liabilities |
| 862 |
|
| 763 |
| |
| Total liabilities |
| 536,169 |
|
| 223,724 |
| |
| Stockholders’ equity (deficit): | |||||||
| Common stock |
| 20 |
|
| 18 |
| |
| Additional paid-in capital |
| 125,406 |
|
| 114,724 |
| |
| Accumulated other comprehensive loss |
| (94 | ) |
| - |
| |
| Accumulated deficit |
| (140,513 | ) |
| (58,173 | ) | |
| Total stockholders' equity (deficit) |
| (15,181 | ) |
| 56,569 |
| |
| Total liabilities and stockholders' equity (deficit) | $ | 520,988 |
| $ | 280,293 |
|
| CUTERA, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (in thousands, except per share data) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||
December 31, |
| December 31, |
| December 31, |
| December 31, | |||||||||
2022 |
| 2021 |
| 2022 |
| 2021 | |||||||||
| Products | $ | 61,601 |
|
| $ | 59,647 |
|
| $ | 228,796 |
|
| $ | 205,703 |
|
| Service |
| 5,752 |
|
|
| 5,982 |
|
|
| 23,603 |
|
|
| 25,567 |
|
| Total net revenue |
| 67,353 |
|
|
| 65,629 |
|
|
| 252,399 |
|
|
| 231,270 |
|
|
|
|
|
|
|
| |||||||||
| Products |
| 26,188 |
|
|
| 23,565 |
|
|
| 100,254 |
|
|
| 83,048 |
|
| Service |
| 2,416 |
|
|
| 3,883 |
|
|
| 12,316 |
|
|
| 15,117 |
|
| Total cost of revenue |
| 28,604 |
|
|
| 27,448 |
|
|
| 112,570 |
|
|
| 98,165 |
|
| Gross profit |
| 38,749 |
|
|
| 38,181 |
|
|
| 139,829 |
|
|
| 133,105 |
|
| Gross margin % |
| 57.5 | % |
|
| 58.2 | % |
|
| 55.4 | % |
|
| 57.6 | % |
|
|
|
|
|
|
| |||||||||
| Operating expenses: |
|
|
|
|
|
|
| ||||||||
| Sales and marketing |
| 28,514 |
|
|
| 24,094 |
|
|
| 106,947 |
|
|
| 76,762 |
|
| Research and development |
| 5,408 |
|
|
| 6,804 |
|
|
| 25,155 |
|
|
| 21,568 |
|
| General and administrative |
| 10,363 |
|
|
| 9,312 |
|
|
| 45,917 |
|
|
| 32,945 |
|
| Total operating expenses |
| 44,285 |
|
|
| 40,210 |
|
|
| 178,019 |
|
|
| 131,275 |
|
| Income (loss) from operations |
| (5,536 | ) |
|
| (2,029 | ) |
|
| (38,190 | ) |
|
| 1,830 |
|
| Interest and other income (expense), net |
|
|
|
|
|
|
| ||||||||
| Amortization of debt issuance costs |
| (438 | ) |
|
| (218 | ) |
|
| (1,355 | ) |
|
| (710 | ) |
| Interest on convertible notes |
| (1,992 | ) |
|
| (777 | ) |
|
| (5,658 | ) |
|
| (2,514 | ) |
| Loss on extinguishment of convertible notes |
| - |
|
|
| - |
|
|
| (34,423 | ) |
|
| - |
|
| Gain on extinguishment of PPP loan |
| - |
|
|
| - |
|
|
| - |
|
|
| 7,185 |
|
| Interest income (expense), net |
| 1,535 |
|
|
| (57 | ) |
|
| 2,600 |
|
|
| (561 | ) |
| Other expense, net |
| (593 | ) |
|
| (373 | ) |
|
| (3,676 | ) |
|
| (1,845 | ) |
| Income (loss) before income taxes |
| (7,024 | ) |
|
| (3,454 | ) |
|
| (80,702 | ) |
|
| 3,385 |
|
| Income tax provision |
| 764 |
|
|
| 481 |
|
|
| 1,638 |
|
|
| 1,323 |
|
| Net income (loss) | $ | (7,788 | ) |
| $ | (3,935 | ) |
| $ | (82,340 | ) |
| $ | 2,062 |
|
|
|
|
|
|
|
| |||||||||
| Net income (loss) per share: |
|
|
|
|
|
|
| ||||||||
| Basic | $ | (0.40 | ) |
| $ | (0.22 | ) |
| $ | (4.39 | ) |
| $ | 0.12 |
|
| Diluted | $ | (0.40 | ) |
| $ | (0.22 | ) |
| $ | (4.39 | ) |
| $ | 0.11 |
|
|
|
|
|
|
|
| |||||||||
| Weighted-average number of shares used in per share calculations: |
|
|
|
|
|
|
| ||||||||
| Basic |
| 19,642 |
|
|
| 17,980 |
|
|
| 18,747 |
|
|
| 17,891 |
|
| Diluted |
| 19,642 |
|
|
| 17,980 |
|
|
| 18,747 |
|
|
| 18,362 |
|
| CUTERA, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
Three Months Ended |
| Twelve Months Ended | |||||||||||||
|
|
|
|
|
|
| |||||||||
December 31, |
| December 31, |
| December 31, |
| December 31, | |||||||||
2022 |
| 2021 |
| 2022 |
| 2021 | |||||||||
| Cash flows from operating activities: | |||||||||||||||
| Net income (loss) | $ | (7,788 | ) | $ | (3,935 | ) | $ | (82,340 | ) | $ | 2,062 |
| |||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||||||||||||||
| Stock-based compensation |
| 1,379 |
|
| 4,665 |
|
| 14,400 |
|
| 13,172 |
| |||
| Depreciation and amortization |
| 1,018 |
|
| 330 |
|
| 2,621 |
|
| 1,344 |
| |||
| Amortization of contract acquisition costs |
| 1,385 |
|
| 427 |
|
| 3,200 |
|
| 1,857 |
| |||
| Amortization of debt issuance costs |
| 438 |
|
| 218 |
|
| 1,355 |
|
| 710 |
| |||
| Unrealized loss on foreign exchange forward |
| 850 |
|
| - |
|
| 558 |
|
| - |
| |||
| Impairment of capitalized cloud computing costs |
| - |
|
| - |
|
| - |
|
| 182 |
| |||
| Change in deferred tax assets |
| 36 |
|
| (189 | ) |
| 188 |
|
| (135 | ) | |||
| Provision for excess and obsolete inventories |
| (1,416 | ) |
| 298 |
|
| (1,306 | ) |
| 1,037 |
| |||
| Provision for credit losses |
| 1,110 |
|
| (14 | ) |
| 1,787 |
|
| 87 |
| |||
| Loss on sale of property and equipment |
| 82 |
|
| - |
|
| 168 |
|
| - |
| |||
| PPP loan forgiveness |
| - |
|
| - |
|
| - |
|
| (7,185 | ) | |||
| Change in right-of-use asset |
| 677 |
|
| 611 |
|
| 2,653 |
|
| 2,292 |
| |||
| Loss on extinguishment of convertible notes |
| - |
|
| - |
|
| 34,423 |
|
| - |
| |||
| Other |
| - |
|
| 46 |
|
| - |
|
| 1 |
| |||
Changes in assets and liabilities: | |||||||||||||||
| Accounts receivable |
| (10,796 | ) |
| (675 | ) |
| (15,900 | ) |
| (9,574 | ) | |||
| Inventories |
| (6,274 | ) |
| (4,308 | ) |
| (34,999 | ) |
| (11,973 | ) | |||
| Other current assets and prepaid expenses |
| (1,214 | ) |
| (1,195 | ) |
| (10,049 | ) |
| (5,766 | ) | |||
| Other long-term assets |
| (4,447 | ) |
| (3,641 | ) |
| (8,091 | ) |
| (7,128 | ) | |||
| Accounts payable |
| 537 |
|
| 632 |
|
| 20,979 |
|
| 1,207 |
| |||
| Accrued liabilities |
| 6,966 |
|
| 9,826 |
|
| 3,282 |
|
| 21,608 |
| |||
| Operating lease liabilities |
| (667 | ) |
| (578 | ) |
| (2,597 | ) |
| (2,151 | ) | |||
| Deferred revenue |
| 1,097 |
|
| 145 |
|
| 2,673 |
|
| (412 | ) | |||
| Net cash provided by (used in) operating activities |
| (17,027 | ) |
| 2,663 |
|
| (66,995 | ) |
| 1,235 |
| |||
| Cash flows from investing activities: | |||||||||||||||
| Acquisition of property and equipment |
| (8,591 | ) |
| (633 | ) |
| (22,698 | ) |
| (1,015 | ) | |||
| Disposal of property and equipment |
| - |
|
| - |
|
| - |
|
| 71 |
| |||
| Proceeds from maturities of marketable investments |
| 111,000 |
|
| - |
|
| 158,000 |
|
| - |
| |||
| Purchase of marketable securities and long-term investments |
| (77,202 | ) |
| - |
|
| (329,484 | ) |
| - |
| |||
| Net cash provided by (used in) investing activities |
| 25,207 |
|
| (633 | ) |
| (194,182 | ) |
| (944 | ) | |||
| Cash flows from financing activities: | |||||||||||||||
| Proceeds from exercise of stock options and employee stock purchase plan |
| 1,036 |
|
| 709 |
|
| 2,723 |
|
| 2,765 |
| |||
| Purchase of capped call |
| (25,009 | ) |
| - |
|
| (56,680 | ) |
| (16,134 | ) | |||
| Payment of issuance costs of capped call |
| - |
|
| - |
|
| (352 | ) |
| - |
| |||
| Proceeds from issuance of convertible notes |
| 120,000 |
|
| - |
|
| 360,000 |
|
| 138,250 |
| |||
| Payment of issuance costs of convertible notes |
| (3,600 | ) |
| - |
|
| (11,202 | ) |
| (4,717 | ) | |||
| Extinguishment of convertible notes |
| - |
|
| - |
|
| (45,776 | ) |
| - |
| |||
| Taxes paid related to net share settlement of equity awards |
| (436 | ) |
| (213 | ) |
| (5,256 | ) |
| (2,176 | ) | |||
| Payments on capital lease obligation |
| (127 | ) |
| (148 | ) |
| (520 | ) |
| (462 | ) | |||
| Net cash provided by financing activities |
| 91,864 |
|
| 348 |
|
| 242,937 |
|
| 117,526 |
| |||
| Net increase (decrease) in cash, cash equivalents and restricted cash |
| 100,044 |
|
| 2,378 |
|
| (18,240 | ) |
| 117,817 |
| |||
| Cash, cash equivalents, and restricted cash at beginning of period |
| 46,580 |
|
| 162,486 |
|
| 164,864 |
|
| 47,047 |
| |||
| Cash, cash equivalents, and restricted cash at end of period | $ | 146,624 |
| $ | 164,864 |
| $ | 146,624 |
| $ | 164,864 |
|
| CUTERA, INC. | |||||||||||||||||||||||
| CONSOLIDATED FINANCIAL HIGHLIGHTS | |||||||||||||||||||||||
| (in thousands, except percentage data) | |||||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||
Three Months Ended |
| % Change |
| Twelve Months Ended |
| % Change | |||||||||||||||||
December 31, |
| December 31, |
| 2022 Vs |
| December 31, |
| December 31, |
| 2022 Vs | |||||||||||||
2022 |
| 2021 |
| 2021 |
| 2022 |
| 2021 |
| 2021 | |||||||||||||
| Revenue By Geography: | |||||||||||||||||||||||
| North America | $ | 34,076 |
|
| $ | 35,827 |
|
| -4.9 | % |
| $ | 128,426 |
|
| $ | 111,621 |
|
| +15.1 | % | ||
| Japan |
| 16,980 |
|
|
| 16,924 |
|
| +0.3 | % |
|
| 64,920 |
|
|
| 70,235 |
|
| -7.6 | % | ||
| Rest of World |
| 16,297 |
|
|
| 12,878 |
|
| +26.5 | % |
|
| 59,053 |
|
|
| 49,414 |
|
| +19.5 | % | ||
| Total Net Revenue | $ | 67,353 |
|
| $ | 65,629 |
|
| +2.6 | % |
| $ | 252,399 |
|
| $ | 231,270 |
|
| +9.1 | % | ||
| International as a percentage of total revenue |
| 49.4 | % |
|
| 45.4 | % |
|
|
|
| 49.1 | % |
|
| 51.7 | % |
|
| ||||
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| Revenue By Product Category: |
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| Systems |
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
| - North America | $ | 25,047 |
|
| $ | 28,747 |
|
| -12.9 | % |
| $ | 98,345 |
|
| $ | 86,100 |
|
| +14.2 | % | ||
| - Rest of World (including Japan) |
| 17,438 |
|
|
| 14,807 |
|
| +17.8 | % |
|
| 65,292 |
|
|
| 53,533 |
|
| +22.0 | % | ||
| Total Systems |
| 42,485 |
|
|
| 43,554 |
|
| -2.5 | % |
|
| 163,637 |
|
|
| 139,633 |
|
| +17.2 | % | ||
| AviClear |
| 3,165 |
|
|
| - |
|
|
|
|
| 4,456 |
|
|
| - |
|
|
| ||||
| Consumables |
| 4,174 |
|
|
| 5,361 |
|
| -22.1 | % |
|
| 18,203 |
|
|
| 16,401 |
|
| +11.0 | % | ||
| Skincare |
| 11,777 |
|
|
| 10,732 |
|
| +9.7 | % |
|
| 42,500 |
|
|
| 49,669 |
|
| -14.4 | % | ||
| Total Products |
| 61,601 |
|
|
| 59,647 |
|
| +3.3 | % |
|
| 228,796 |
|
|
| 205,703 |
|
| +11.2 | % | ||
| Service |
| 5,752 |
|
|
| 5,982 |
|
| -3.8 | % |
|
| 23,603 |
|
|
| 25,567 |
|
| -7.7 | % | ||
| Total Net Revenue | $ | 67,353 |
|
| $ | 65,629 |
|
| +2.6 | % |
| $ | 252,399 |
|
| $ | 231,270 |
|
| +9.1 | % | ||
Three Months Ended |
|
|
| Twelve Months Ended | |||||||||||
December 31, |
| December 31, |
|
|
| December 31, |
| December 31, | |||||||
2022 |
| 2021 |
|
|
| 2022 |
| 2021 | |||||||
| Pre-tax Stock-Based Compensation Expense: | |||||||||||||||
| Cost of revenue | $ | 235 | $ | 500 | $ | 1,665 | $ | 1,408 | |||||||
| Sales and marketing | 1,143 | 1,206 | 4,998 | 3,160 | |||||||||||
| Research and development | (108 | ) | 1,156 | 2,405 | 2,784 | ||||||||||
| General and administrative | 109 | 1,803 | 5,332 | 5,820 | |||||||||||
| $ | 1,379 | $ | 4,665 | $ | 14,400 | $ | 13,172 |
CUTERA, INC. Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (in thousands) (unaudited) | ||||||||||
| Three Months Ended December 31, 2022 | Gross Profit | Gross Margin | Operating Income | |||||||
| Reported | $ | 38,749 | 57.5 | % | $ | (5,536 | ) | |||
| Adjustments: | ||||||||||
| Depreciation and amortization including contract acquisition costs |
| 997 | 1.5 | % |
| 2,479 |
| |||
| Stock-based compensation |
| 235 | 0.3 | % |
| 1,379 |
| |||
| ERP implementation cost |
| - | - |
|
| 1,498 |
| |||
| Legal - Lutronic |
| - | - |
|
| 222 |
| |||
| Severance |
| - | - |
|
| 200 |
| |||
| Other adjustments |
| - | - |
|
| - |
| |||
| Total adjustments |
| 1,232 | 1.8 | % |
| 5,778 |
| |||
| Adjusted | $ | 39,981 | 59.4 | % | $ | 242 |
| |||
| Three Months Ended December 31, 2021 | Gross Profit | Gross Margin | Operating Income | |||||||
| Reported | $ | 38,181 | 58.2 | % | $ | (2,029 | ) | |||
| Adjustments: | ||||||||||
| Depreciation and amortization including contract acquisition costs |
| 94 | 0.1 | % |
| 740 |
| |||
| Stock-based compensation |
| 500 | 0.8 | % |
| 4,665 |
| |||
| ERP implementation cost |
| - | - |
|
| 711 |
| |||
| Legal - Lutronic |
| - | - |
|
| 222 |
| |||
| Severance |
| - | - |
|
| - |
| |||
| Other adjustments |
| - | - |
|
| - |
| |||
| Total adjustments |
| 594 | 0.9 | % |
| 6,338 |
| |||
| Adjusted | $ | 38,775 | 59.1 | % | $ | 4,309 |
|
| Twelve Months Ended December 31, 2022 | Gross Profit | Gross Margin | Operating Income | ||||||||
| Reported | $ | 139,829 |
| 55.4 | % | $ | (38,190 | ) | |||
| Adjustments: | |||||||||||
| Depreciation and amortization including contract acquisition costs |
| 1,593 |
| 0.6 | % |
| 5,821 |
| |||
| Stock-based compensation |
| 1,665 |
| 0.7 | % |
| 14,400 |
| |||
| ERP implementation cost |
| - |
| - |
|
| 9,210 |
| |||
| Legal - Lutronic |
| - |
| - |
|
| 1,284 |
| |||
| Severance |
| 26 |
| 0.0 | % |
| 615 |
| |||
| Other adjustments |
| (290 | ) | -0.1 | % |
| (290 | ) | |||
| Total adjustments |
| 2,994 |
| 1.2 | % |
| 31,040 |
| |||
| Adjusted | $ | 142,823 |
| 56.6 | % | $ | (7,150 | ) | |||
| Twelve Months Ended December 31, 2021 | Gross Profit | Gross Margin | Operating Income | ||||||||
| Reported | $ | 133,105 |
| 57.6 | % | $ | 1,830 |
| |||
| Adjustments: | |||||||||||
| Depreciation and amortization including contract acquisition costs |
| 526 |
| 0.2 | % |
| 3,188 |
| |||
| Stock-based compensation |
| 1,408 |
| 0.6 | % |
| 13,172 |
| |||
| ERP implementation cost |
| - |
| - |
|
| 1,498 |
| |||
| Legal - Lutronic |
| - |
| - |
|
| 1,201 |
| |||
| Severance |
| - |
| - |
|
| 638 |
| |||
| Other adjustments |
| (791 | ) | -0.4 | % |
| (791 | ) | |||
| Total adjustments |
| 1,143 |
| 0.4 | % |
| 18,906 |
| |||
| Adjusted | $ | 134,248 |
| 58.0 | % | $ | 20,736 |
|
View source version on businesswire.com:https://www.businesswire.com/news/home/20230228005596/en/
CONTACT: Cutera, Inc.
Greg Barker
VP, Corporate FP&A
415-657-5500
IR@cutera.com
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH MEDICAL DEVICES
SOURCE: Cutera, Inc.
Copyright Business Wire 2023.
PUB: 02/28/2023 04:01 PM/DISC: 02/28/2023 04:03 PM
http://www.businesswire.com/news/home/20230228005596/en